1995
Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease
Price L, Spencer D, Marek K, Robbins R, Leranth C, Farhi A, Naftolin F, Roth R, Bunney B, Hoffer P, Makuch R, Redmond D. Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease. Biological Psychiatry 1995, 38: 498-505. PMID: 8562661, DOI: 10.1016/0006-3223(95)00129-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBrain Tissue TransplantationCaudate NucleusDepressive DisorderDopamineFemaleFetal Tissue TransplantationFollow-Up StudiesHumansMaleMesencephalonMiddle AgedNeurocognitive DisordersNeuropsychological TestsPanic DisorderParkinson DiseasePostoperative ComplicationsProspective StudiesConceptsParkinson's diseasePsychiatric statusHuman fetal mesencephalic tissueAdrenal medullary graftsAdrenal medullary transplantationFetal mesencephalic tissueSystematic psychiatric assessmentPerioperative sequelaeMesencephalic tissuePsychiatric sequelaeCaudate nucleusPsychiatric assessmentNeurobiological effectsBehavioral symptomsTissue transplantationDiseasePatientsTransplantationSequelaeSuch episodesEpisodesGroup effectsStatusDeliriumDiscrete episodesGeneral Cognitive Ability Following Unilateral and Bilateral Fetal Ventral Mesencephalic Tissue Transplantation for Treatment of Parkinson's Disease
Sass K, Buchanan C, Westerveld M, Marek K, Farhi A, Robbins R, Naftolin F, Vollmer T, Leranth C, Roth R, Price L, Bunney B, Elsworth J, Hoffer P, Redmond D, Spencer D. General Cognitive Ability Following Unilateral and Bilateral Fetal Ventral Mesencephalic Tissue Transplantation for Treatment of Parkinson's Disease. JAMA Neurology 1995, 52: 680-686. PMID: 7619024, DOI: 10.1001/archneur.1995.00540310050016.Peer-Reviewed Original ResearchConceptsCognitive abilitiesNonverbal cognitive abilityVerbal cognitive abilityInformation-processing speedVerbal memoryNeuropsychological profileTest batteryCognitive functionNormal cognitive functionCognitive dysfunctionRight caudate nucleusCaudate nucleusFactor analysisTissue transplantationParkinson's disease
1993
Cellular replacement of dopamine deficit in Parkinson's disease using human fetal mesencephalic tissue: preliminary results in four patients.
Redmond D, Robbins R, Naftolin F, Marek K, Vollmer T, Leranth C, Roth R, Price L, Gjedde A, Bunney B. Cellular replacement of dopamine deficit in Parkinson's disease using human fetal mesencephalic tissue: preliminary results in four patients. Proceedings Of The Association For Research In Nervous And Mental Disease 1993, 71: 325-59. PMID: 8417471.Peer-Reviewed Original Research
1992
Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease
Spencer D, Robbins R, Naftolin F, Marek K, Vollmer T, Leranth C, Roth R, Price L, Gjedde A, Bunney B, Sass K, Elsworth J, Kier E, Makuch R, Hoffer P, Redmond D. Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease. New England Journal Of Medicine 1992, 327: 1541-1548. PMID: 1435880, DOI: 10.1056/nejm199211263272201.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAdultAntiparkinson AgentsCaudate NucleusCryopreservationCyclosporineDopamineFemaleFetal Tissue TransplantationHomovanillic AcidHumansMagnetic Resonance ImagingMaleMesencephalonMiddle AgedMotor ActivityParkinson DiseasePutamenStereotaxic TechniquesTomography, Emission-ComputedConceptsCase patientsParkinson's diseaseMesencephalic tissueCaudate nucleusHuman fetal ventral mesencephalic tissueFetal ventral mesencephalic tissueHuman fetal mesencephalic tissueContinued disease progressionFetal dopaminergic neuronsFetal mesencephalic tissueVentral mesencephalic tissueSevere Parkinson's diseaseOptimal drug therapySigns of parkinsonismMidbrain dopamine neuronsPositron emission tomographyMonths of evaluationAntiparkinsonian medicationUnilateral transplantationDrug holidayMore medicationsStriatonigral degenerationNeurologic functionDopaminergic neuronsDrug therapyClozapine: A Hypothesised Mechanism for its Unique Clinical Profile
Bunney B. Clozapine: A Hypothesised Mechanism for its Unique Clinical Profile. The British Journal Of Psychiatry. Supplement 1992, 160: 17-21. PMID: 1418885, DOI: 10.1192/s0007125000296864.Peer-Reviewed Original Research
1991
Midbrain dopamine system electrophysiological functioning: A review and new hypothesis
Bunney B, Chiodo L, Grace A. Midbrain dopamine system electrophysiological functioning: A review and new hypothesis. Synapse 1991, 9: 79-94. PMID: 1821487, DOI: 10.1002/syn.890090202.Peer-Reviewed Original ResearchMechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia
Deutch A, Moghaddam B, Innis R, Krystal J, Aghajanian G, Bunney B, Charney D. Mechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia. Schizophrenia Research 1991, 4: 121-156. PMID: 1674882, DOI: 10.1016/0920-9964(91)90030-u.Peer-Reviewed Original ResearchConceptsAtypical antipsychotic drugsAntipsychotic drugsDopamine D2 receptor antagonismD2 receptor antagonismAtypical profileNovel therapeutic strategiesDopamine D2 receptorsMechanism of actionAtypical agentsReceptor antagonismClinical dataD2 receptorsTherapeutic strategiesDrug profileDrugs implicationsMode of actionDrugsAntagonismClozapineRacloprideSerotoninSubtypesSchizophrenia
1988
Effects of Acute and Chronic Neuroleptic Treatment on the Activity of Mid brain Dopamine Neuronsa
BUNNEY B. Effects of Acute and Chronic Neuroleptic Treatment on the Activity of Mid brain Dopamine Neuronsa. Annals Of The New York Academy Of Sciences 1988, 537: 77-85. PMID: 2904786, DOI: 10.1111/j.1749-6632.1988.tb42097.x.Peer-Reviewed Original ResearchConceptsAD administrationDA releaseDA cell activityChronic neuroleptic treatmentMidbrain DA neuronsRelease of DAEffects of AcuteNeurological side effectsDA neuronsNeuroleptic treatmentAcute effectsNerve terminalsSpontaneous activitySide effectsCell activityMarked increaseAdministrationProjection areaPrimary effectReleaseAcuteMarked effectNeuronsActivityBiochemical techniques
1987
Chronic Neuroleptic Effects on Dopamine Neuron Activity: A Model for Predicting Therapeutic Efficacy and Side Effects?
Freeman A, Bunney B. Chronic Neuroleptic Effects on Dopamine Neuron Activity: A Model for Predicting Therapeutic Efficacy and Side Effects? Psychopharmacology Series 1987, 3: 225-235. PMID: 2881290, DOI: 10.1007/978-3-642-71288-3_26.Peer-Reviewed Original ResearchConceptsMost psychotic patientsDA receptor blockerTreatment of choiceDopamine neuron activityCentral catecholamine systemsReceptor blockadeReceptor blockersCatecholamine neuronsNeuroleptic effectsMajor symptomsAntipsychotic drugsCatecholamine systemsAntipsychotic propertiesForebrain regionsNeuronal activityCatecholamine receptorsSide effectsDopamine systemNeuron activityPsychotic patientsTherapeutic efficacyMode of actionFeedback pathwaysTreatmentNeuroleptics
1986
Does the cholecystokinin antagonist proglumide possess antipsychotic activity?
Innis R, Bunney B, Charney D, Price L, Glazer W, Sternberg D, Rubin A, Heninger G. Does the cholecystokinin antagonist proglumide possess antipsychotic activity? Psychiatry Research 1986, 18: 1-7. PMID: 3737785, DOI: 10.1016/0165-1781(86)90056-9.Peer-Reviewed Original ResearchConceptsPsychosis ratingsPlacebo-controlled studyRole of cholecystokininCentral dopaminergic activityCCK receptor antagonistsPathogenesis of schizophreniaMesocortical neuronsNeuroleptic medicationNeurotransmitter statusReceptor antagonistDopaminergic activityAntipsychotic activitySchizophrenic patientsCholecystokininNegative findingsPreclinical researchProglumidePatientsSchizophreniaPotential reasonsMedicationsPathogenesisAntagonistMidbrainNeuropeptides
1985
The treatment of tardive dyskinesia with baclofen
Glazer W, Moore D, Bowers M, Bunney B, Roffman M. The treatment of tardive dyskinesia with baclofen. Psychopharmacology 1985, 87: 480-483. PMID: 3936106, DOI: 10.1007/bf00432517.Peer-Reviewed Original ResearchFurther Studies on the Specificity of Proglumide as a Selective Cholecystokinin Antagonist in the Central Nervous Systema
BUNNEY B, CHIODO L, FREEMAN A. Further Studies on the Specificity of Proglumide as a Selective Cholecystokinin Antagonist in the Central Nervous Systema. Annals Of The New York Academy Of Sciences 1985, 448: 345-351. PMID: 2862828, DOI: 10.1111/j.1749-6632.1985.tb29929.x.Peer-Reviewed Original Research
1980
Changing Concepts of Nigral Dopamine System Function Within the Basal Ganglia: Relevance to Extrapyramidal Disorders
Bunney B, Grace A, Hommer D. Changing Concepts of Nigral Dopamine System Function Within the Basal Ganglia: Relevance to Extrapyramidal Disorders. Journal Of Neural Transmission. Supplementa 1980, 17-23. PMID: 6107330, DOI: 10.1007/978-3-7091-8582-7_3.Peer-Reviewed Original ResearchConceptsBasal gangliaExtrapyramidal disordersDopaminergic systemNigral dopaminergic systemExtrapyramidal motor systemDopamine system functionStriatal outputSubstantia nigraNeurotransmitter systemsBrain pathwaysGangliaBrain regionsDisordersSensory inputMotor systemSystem functionSymptomsPathwayBrainNigra